RT Journal Article
SR Electronic
T1 Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 957
OP 964
DO 10.21873/anticanres.14029
VO 40
IS 2
A1 SHINICHIRO OKAUCHI
A1 TAKESHI NUMATA
A1 TAKESHI NAWA
A1 HIDEO ICHIMURA
A1 TAKEFUMI SAITO
A1 KENJI HAYASHIHARA
A1 HIDEYASU YAMADA
A1 HIROAKI SATOH
A1 TAKESHI ENDO
A1 YOSHIHISA INAGE
A1 TAKAYUKI KABURAGI
A1 MORIYUKI KIYOSHIMA
A1 YUTAKA YAMADA
A1 TOMOHIRO TAMURA
A1 KAZUHITO SAITO
A1 MASAHARU INAGAKI
A1 NOBUYUKI HIZAWA
A1 YUKIO SATO
A1 TOSHIHIRO SHIOZAWA
A1 IKUO SEKINE
A1 HIROICHI ISHIKAWA
A1 KOICHI KURIHIMA
A1 MITSUAKI SAKAI
A1 KOICHI KAMIYAMA
A1 MASAKI KIMURA
A1 NORIHIRO KIKUCHI
A1 HIROYUKI NAKAMURA
A1 KINYA FURUKAWA
A1 TAKAHIDE KODAMA
A1 KUNIHIKO MIYAZAKI
A1 TAKAAKI YAMASHITA
A1 SHIGEN HAYASHI
A1 YASUNORI FUNAYAMA
A1 AKIHIRO NOMURA
YR 2020
UL http://ar.iiarjournals.org/content/40/2/957.abstract
AB Background/Aim: To describe real clinical outcomes when using systemic therapy to treat non-small cell lung cancer (NSCLC) patients who have anaplastic lymphoma kinase (ALK) fusion gene mutation. Patients and Methods: We performed a retrospective chart review from April 2008 to March 2019 sourced from 16 medical institutes that cover a population of three million people. Results: There were 129 ALK rearranged NSCLC patients. Among them, 103 patients including 40 recurrent disease cases received ALK-tyrosine kinase inhibitors (TKI) and chemotherapy. Our treatment results were comparable to previously reported clinical trials and clinical practice studies. First-line alectinib, treatment sequence of ALK-TKI followed by another ALK-TKI, and pemetrexed-containing chemotherapy contributed to the outcome of treatment. Conclusion: By arrangement of treatment such as treatment sequence of ALK-TKI and chemotherapy regimen, it might be possible to obtain a treatment outcome almost equivalent to those of clinical trials even in real clinical practice.